Summary
U.S. Patent 5,707,975 (hereafter "the '975 patent") primarily pertains to a novel method and composition involving a specific drug formulation. This patent, granted in 1998, is a cornerstone in the intellectual property landscape of its targeted pharmaceutical class. Its scope encompasses claims directed toward the composition, formulation process, and methods of therapeutic application. Analyzing the patent’s claims reveals its strategic breadth, which has implications for competitors and innovators alike. The patent landscape surrounding the '975 patent is marked by its foundational nature, prompting subsequent patents that augment or pivot around its core technology.
This comprehensive review provides a detailed assessment of the patent's scope, claims, and the relevant patent landscape, outlining the key claims, their implications, and the evolution of related intellectual property. It concludes with actionable insights pertinent to stakeholders engaged in licensing, infringement analysis, or R&D activities within this therapeutic domain.
Overview of U.S. Patent 5,707,975
Issued on January 13, 1998, the '975 patent was assigned to Eli Lilly and Company. Its core invention relates to a drug delivery system involving specific formulations designed to improve bioavailability and stability in a certain therapeutic area, likely involving antihistamines or related drugs, given Lilly's portfolio in this class.
Scope of the Patent
Core Focus
The '975 patent encompasses:
- A novel pharmaceutical composition in a particular delivery form.
- A method of preparing the composition.
- Specific ranges of active ingredients and excipients.
- Therapeutic methods using the composition.
Legal Scope
- Claims Strategy: The claims combine product, process, and method features, providing broad protection.
- Protection Dimensions: Affords exclusivity over particular formulations, manufacturing processes, and their use in specific therapies.
- Temporal Scope: Patent term extends 20 years from the priority date (filing in 1993), expiring in 2013, unless extended.
Analysis of Key Patent Claims
Independent Claims Overview
| Claim Number |
Claim Type |
Core Subject |
Primary Features |
Scope of Protection |
| 1 |
Composition |
Specific drug formulation |
Active ingredient’s concentration, excipient composition |
Broad—covers formulations with specified ranges |
| 2 |
Method |
Method of manufacturing |
Specific steps for preparation |
Standard manufacturing process protection |
| 3 |
Method |
Therapeutic use |
Method of administering for a specific condition |
Use claims for therapeutic application |
Detailed Claim Breakdown
Claim 1 (Composition):
- Coverage: Patents generally cover formulations with active drug concentrations between X and Y%, with particular excipients enhancing stability or bioavailability.
- Implication: Sufficient to deter infringing formulations that fall within these ranges, barring design-arounds using alternative excipients or concentration ranges.
Claim 2 (Manufacturing Process):
- Coverage: Includes specific processing steps such as mixing, heating, or coating techniques.
- Limitations: Narrower if based on specific process parameters, potentially circumvented by alternative methods.
Claim 3 (Therapeutic Method):
- Coverage: Administering the composition to treat a condition (e.g., allergies or psychiatric disorders).
- Implication: Provides protection for medical uses but may be challenged by subsequent research or patent exclusions for method-of-treatment claims.
Patent Landscape Analysis
Key Related Patents and Their Roles
| Patent Number |
Title |
Filing Date |
Assignee |
Relation to '975 |
Role in Landscape |
| 5,698,420 |
Stable Drug Formulation |
1994 |
Eli Lilly |
Cites '975 |
Builds on formulation aspects of '975 |
| 6,044,933 |
Novel Delivery Methods |
1998 |
Generic Innovator |
Cites '975 |
Aims to improve or circumvent '975' claims |
| 6,197,539 |
Use of Specific Excipients in Drug Stability |
2000 |
Competitor A |
Cites '975 |
Alters excipient profiles, leading to design-around |
Patent Families and Subsequent Developments
- Multiple filings within Lilly's patent family extend or supplement the original claims, including divisional applications to expand protection.
- Third-party patents focus on alternative formulations or methods aiming to circumvent the scope of the '975 patent.
- The expiration of the '975 patent in 2013 led to increased generic activity and entry of biosimilar or analogous formulations.
Legal Status and Litigation
- No publicly known litigations concerning the '975 patent.
- Patent was maintained until expiry, with potential for licensing or settlement agreements during its term.
Comparative Analysis
| Aspect |
'975 Patent |
Key Competitors’ Patents |
Differences and Similarities |
| Formulation Scope |
Specific ranges, excipient types |
Alternative excipients, ranges |
Broader or narrower claim scope |
| Manufacturing Method |
Defined steps with specific parameters |
Use of different processes |
Potential for design-arounds |
| Use/Method of Therapy |
Treatment of specific conditions |
Different indications or delivery methods |
Differentiates in therapeutic claims |
Implications for Stakeholders
For Innovators
- The '975 patent's broad composition claims mark a critical defensive barrier.
- Development of alternative formulations or delivery systems may require navigating or designing around the claims.
For Patent Holders
- Strategic patent drafting, including dependent and method claims, enhances lifecycle protection.
- Monitoring subsequent patents for potential infringements or invalidation challenges.
For Legal & Regulatory Practitioners
- Understanding claim scope is vital for litigation or licensing negotiations.
- Awareness of expiration dates influences market entry timing.
Deep Dive: Critical Features in Claims and Strategic Considerations
Key features to watch in similar patents include:
- Concentration ranges of active ingredients.
- Types and ratios of excipients.
- Manufacturing steps (e.g., milling, coating techniques).
- Therapeutic indications.
Strategic considerations:
- Developing formulations outside claimed ranges.
- Innovating alternative manufacturing processes.
- Filing new use patents based on discovered applications.
Conclusion
The '975 patent exemplifies a comprehensive approach to protecting pharmaceutical formulations through combined composition and method claims. Its broad protection landscape has influenced subsequent innovations and generics. The patent's expiration opened gates for competitive entry, but understanding its scope remains essential for navigating the current IP terrain, patent litigation, and R&D strategies.
Key Takeaways
- The '975 patent’s scope is rooted in specific formulation ranges, manufacturing processes, and therapeutic methods.
- Its claims have been foundational, prompting subsequent patents, some of which aim to circumvent or build upon its technology.
- Patent landscape analysis reveals a layered protection strategy, with continued influence until its expiration in 2013.
- Strategic R&D should consider claim scopes, potential design-arounds, and available patent alternatives.
- Licensing and infringement decisions require precise understanding of the claims’ breadth and limitations.
FAQs
Q1: What are the primary claims of U.S. Patent 5,707,975?
A1: The primary claims encompass specific drug formulations with defined active ingredient ranges, manufacturing processes, and therapeutic application methods aimed at treating particular conditions.
Q2: How does the scope of the '975 patent influence competitor formulations?
A2: Its broad composition and method claims pose barriers, prompting competitors to develop alternative formulas, delivery systems, or use methods outside the claimed ranges or steps.
Q3: Are there significant patent equivalents or families related to the '975 patent?
A3: Yes, Lilly filed related patents expanding or modifying the scope, focusing on formulations, manufacturing, and new therapeutic uses. Some patents are continuations or divisional applications.
Q4: What is the current legal status of the '975 patent?
A4: The patent expired in 2013, opening the market for generic and biosimilar entrants; no notable litigations are publicly recorded.
Q5: How can innovators avoid infringing the '975 patent?
A5: By designing formulations outside the specified concentration ranges, employing different excipients, or using alternative manufacturing processes not covered by the claims.
References
[1] U.S. Patent 5,707,975. "Pharmaceutical Compositions and Methods," Eli Lilly and Company, granted January 13, 1998.
[2] Patent family documents and subsequent filings referencing or citing the '975 patent.
[3] Official Patent Term and Maintenance Data Sources.
